Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases

2021 ◽  
Author(s):  
Hannah Lu Chang ◽  
Amy Little Jones
Keyword(s):  
Liver Metastases ◽  
Current Status ◽  
Borderline Resectable ◽  
Perioperative Treatment

scholarly journals The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Andre Gorgen ◽  
Hala Muaddi ◽  
Wei Zhang ◽  
Ian McGilvray ◽  
Steven Gallinger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Transplantation ◽  
Liver Resection ◽  
Liver Metastases ◽  
Current Status ◽  
Main Concern ◽  
Organ Shortage ◽  
Donor Liver Transplantation ◽  
Live Donor Liver ◽  
The Impact

Colorectal cancer (CRC) is the third most incident cancer worldwide. Most of CRC patients will develop distant metastases, mainly to the liver, and liver resection is the only potential chance for cure. On the other hand, only a small proportion of patients with hepatic CRC metastasis are candidates for upfront liver resection. Liver transplantation (LT) is an attractive option for patients with nonresectable CRC liver metastases (NRCLM) without extrahepatic involvement. Initial experiences with LT for NRCLM achieved very poor outcomes, with a 5-year overall survival (OS) lower than 20%. However, these initial studies did not have a standardized patient selection or neoadjuvant or adjuvant therapies. With recent advances in the surgical and medical oncology fields, the landscape has changed. Recent studies from Norway have shown an encouraging 5-year OS of 50% when transplanting patients with NRCLM. Nevertheless, the main concern when expanding the indications for LT is organ shortage. To manage this organ shortage, strategies utilizing live donor liver transplantation are gaining favor. A few ongoing trials are assessing the impact of LT in NRCLM patient survival. Therefore, the aim of this paper is to review the current status of LT for NRCLM.

Ablation of Liver Metastases: Current Status

2010 ◽  
Vol 21 (8) ◽  
pp. S214-S222 ◽  
Author(s):  
Vincent L. Flanders ◽  
Debra A. Gervais
Keyword(s):  
Liver Metastases ◽  
Current Status

Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases

2015 ◽  
Vol 33 (21) ◽  
pp. 2405-2406 ◽  
Author(s):  
John N. Primrose ◽  
David Cunningham ◽  
O. James Garden ◽  
Tim S. Maughan ◽  
Siân A. Pugh ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Perioperative Treatment

scholarly journals Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer

2020 ◽  
Vol 25 (2) ◽  
pp. 72-82
Author(s):  
Min Je Sung ◽  
Seungmin Bang
Keyword(s):  
Pancreatic Cancer ◽  
Poor Response ◽  
Chemotherapeutic Agents ◽  
Chemoradiation Therapy ◽  
Current Status ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
The Poor ◽  
Polymerase Inhibitors ◽  
Concurrent Chemoradiation Therapy

Pancreatic cancer is still one of the most aggressive malignancy, showing 10% of 5-year survival. Among the several reasons of the grave prognosis, the poor response to chemotherapeutic agents and the absence of effective tool for early detection are the most important. Regarding treatments, surgical resection is still positioned as the only one for expecting the cure of pancreatic cancer. However, the rate of recurrence after surgery is still high as more than 50%. And the portion of patients who are diagnosed at the resectable stage is still less than 15% of all cases. So, chemotherapy and radiotherapy are the main players for combating with pancreatic cancer. After the introduction of outcomes of FOLFIRINOX, and gemcitabine/nabpaclitaxel for metastatic pancreatic cancer, two-digit overall survival can be expected. And, neoadjuvant treatments including concurrent chemoradiation therapy for borderline resectable pancreatic cancer and/or resectable pancreatic cancer are reported as superior to upfront surgery. More recently, several target agents including polyadenosine diphosphate-ribose polymerase inhibitors and immunologic drugs are under evaluation for pancreatic cancer. So, herein, current status of chemotherapy and radiation therapy for pancreatic cancer will be addressed.

Transarterial chemoembolization (TACE) for colorectal liver metastases—current status and critical review

2015 ◽  
Vol 400 (6) ◽  
pp. 641-659 ◽  
Author(s):  
Alexander Massmann ◽  
Thomas Rodt ◽  
Steffen Marquardt ◽  
Roland Seidel ◽  
Katrina Thomas ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Critical Review ◽  
Transarterial Chemoembolization ◽  
Colorectal Liver Metastases ◽  
Current Status

Predicting liver metastases growth patterns: Current status and future possibilities

2020 ◽  
Author(s):  
Rui Caetano Oliveira ◽  
Henrique Alexandrino ◽  
Maria Augusta Cipriano ◽  
Filipe Caseiro Alves ◽  
José Guilherme Tralhão
Keyword(s):  
Liver Metastases ◽  
Growth Patterns ◽  
Current Status
Sign in / Sign up

Export Citation Format

Share Document